Therna

Link to the post: blog.therna.com/p/designing-me…

Individualized medicine is moving from concept to reality. New FDA guidance supports therapies designed for single patients with ultra rare diseases. At Therna Biosciences, we are building an AI enabled RNA platform to make this possible. Link to our CEO’s post in the comments

Link to the feature: criver.com/insights/ai-en…

AI-enabled RNA design for ultra-rare diseases was on stage at PMWC and in a new Charles River feature last week. Two signs of a growing conversation around what is now possible. Link in comments. #RNA #PrecisionMedicine #RareDisease

@PMWCintl Read the full announcement here: prnewswire.com/news-releases/…

Two urgent patients. One AI-driven approach. At @PMWCintl , we are unveiling our collaboration with Charles River Labs to advance single-patient RNA medicines for ultra-rare conditions. Our AI platform designed better candidates, faster. #PrecisionMedicine #RareDisease #RNA

Evo 2, the largest fully open biological AI model to date, is now published in @Nature.

Therna Biosciences Appoints Biotech Veteran Devyn Smith, Ph.D., to Board of Directors and Expands Strategic and Scientific Advisory Leadership: Read the full news here: prnewswire.com/news-releases/…

We started Therna Biosciences in April 2025 with a simple belief: RNA is a language that can be learned and engineered. One year in, we built a lab in the loop AI platform, launched from stealth, and partnered with NVIDIA on CodonFM. A Look back in comments.

Therna Biosciences has joined the NVIDIA Inception program, building on our work with NVIDIA and CodonFM to advance AI-driven RNA design and programmable RNA therapeutics. #NVIDIAInception #AI #RNA

Foundation models are essential for biology. Scaling is not failing but requires the right customization. They are indispensable in data-sparse domains and will drive the next decade of discovery. blog.therna.com/p/the-case-for…

Excited to announce the launch of Therna Biosciences, The RNA company. By combining RNA biology with generative AI, we’re building programmable RNA medicines with greater durability, specificity and efficacy. Backed by $10M seed funding. webwire.com/ViewPressRel.a…